We then used the optimized surface to profile CD9, EGFR,and PD-L1 surface proteins of sEVs derived from non-small cell lungcancer (NSCLC) cell-line H1975, before and after treatment with EGFRtyrosine kinase inhibitors, as well as sEVs derived from pleural effusionfluid of NSCLC adenocarcinoma patients. This evidence concerns the gene CD9 and non-small cell lung carcinoma.